Santhera suffers as Catena fails second pivotal Friedreich's ataxia trial
This article was originally published in Scrip
Executive Summary
Santhera Pharmaceuticals' Catena (also known as Sovrima; idebenone) has failed a Phase III trial in Friedreich's ataxia, marking the drug's second pivotal trial failure in this indication. The company's share price closed down around 45% on 20 May, at CHF14.10 ($12.27), on the Swiss stock exchange.